Dec 14 (Reuters) - Apellis Pharmaceuticals said on Thursday the European drug regulator's advisory panel may decline to back an authorization for the company's drug for a chronic eye disease. (Reporting by Leroy Leo in Bengaluru; Editing by Mrigank Dhaniwala)
Market Closed -
Other stock markets
|
After market 01:55:03 am | |||
39.68 USD | -8.99% | 40.5 | +2.08% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-33.71% | 529.15Cr | |
-1.62% | 8.92TCr | |
+1.32% | 4.05TCr | |
-15.73% | 3.28TCr | |
+64.13% | 2.62TCr | |
-21.28% | 1.45TCr | |
-8.50% | 1.31TCr | |
-44.07% | 1.16TCr | |
-13.06% | 1.15TCr | |
+4.94% | 881.83Cr |
- Stock Market
- Equities
- APLS Stock
- News Apellis Pharmaceuticals, Inc.
- Apellis says EU regulator panel may not back its eye disease drug